PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Opioid Abatement Funds and MOUD Use: Null Main Effects, Exploratory Signal

opioid abatement fundsopioid settlementmedications for opioid use disorderMOUDbuprenorphinemethadonesupplantationsynthetic difference-in-differenceshealth policyopioid stewardshipquasi-experimental Behavioral Health / Addiction Medicine

Background Information

How state spending influences opioid use disorder treatment admissions.

This study explores how state-level opioid abatement fund allocations impact the utilization of medications for opioid use disorder (MOUD). Funding to general treatment programs increased substance use treatment admissions by 13.2% but not MOUD utilization. In states prohibiting fund supplantation, MOUD admissions increased significantly. The findings suggest that appropriate allocation of funds, particularly in states prohibiting supplantation, could enhance MOUD use; however, results are based on early data with limited comparison states. States prohibiting fund supplantation showed significant increases in MOUD admissions.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Shi JS, Wen H

Citation: Shi JS, Wen H The Effect of Opioid Abatement Funds on the Utilization of Medications for Opioid Use Disorder. Health services research. 2026;61(6). doi:10.1111/1475-6773.70173

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.